AnteoTech Limited (ADO.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 460.39 Thousand AUD | 25.89% |
| 2023 | 365.72 Thousand AUD | -51.93% |
| 2022 | 760.87 Thousand AUD | -15.28% |
| 2021 | 898.06 Thousand AUD | 199.95% |
| 2020 | 299.4 Thousand AUD | 8.36% |
| 2019 | 276.31 Thousand AUD | -71.84% |
| 2018 | 981.31 Thousand AUD | -60.3% |
| 2017 | 2.47 Million AUD | 3.36% |
| 2016 | 2.39 Million AUD | 410.07% |
| 2015 | 468.78 Thousand AUD | 51.34% |
| 2014 | 309.75 Thousand AUD | -39.3% |
| 2013 | 510.29 Thousand AUD | 25.94% |
| 2012 | 405.17 Thousand AUD | 92.88% |
| 2011 | 210.06 Thousand AUD | -20.96% |
| 2010 | 265.75 Thousand AUD | -60.61% |
| 2009 | 674.61 Thousand AUD | -40.59% |
| 2008 | 1.13 Million AUD | -38.84% |
| 2007 | 1.85 Million AUD | 129.33% |
| 2006 | 809.6 Thousand AUD | -59.35% |
| 2005 | 1.99 Million AUD | -53.47% |
| 2004 | 4.28 Million AUD | 10.38% |
| 2003 | 3.87 Million AUD | 207.03% |
| 2002 | 1.26 Million AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | -3.69 Million AUD | 0.0% |
| 2024 FY | 460.39 Thousand AUD | 25.89% |
| 2024 Q2 | 379.13 Thousand AUD | 0.0% |
| 2023 Q2 | 287.78 Thousand AUD | 0.0% |
| 2023 FY | 365.72 Thousand AUD | -51.93% |
| 2023 Q4 | 77.94 Thousand AUD | 0.0% |
| 2022 FY | 760.87 Thousand AUD | -15.28% |
| 2022 Q4 | 392.4 Thousand AUD | 0.0% |
| 2022 Q2 | 368.46 Thousand AUD | 0.0% |
| 2021 FY | 898.06 Thousand AUD | 199.95% |
| 2021 Q2 | 545.58 Thousand AUD | 0.0% |
| 2021 Q4 | 352.48 Thousand AUD | 0.0% |
| 2020 Q4 | 208.99 Thousand AUD | 0.0% |
| 2020 FY | 299.4 Thousand AUD | 8.36% |
| 2020 Q2 | 90.41 Thousand AUD | 0.0% |
| 2019 FY | 276.31 Thousand AUD | -71.84% |
| 2019 Q2 | 209.41 Thousand AUD | 0.0% |
| 2019 Q4 | 66.9 Thousand AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q2 | 140.17 Thousand AUD | 0.0% |
| 2018 FY | 981.31 Thousand AUD | -60.3% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 FY | 2.47 Million AUD | 3.36% |
| 2017 Q2 | 2.22 Million AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q2 | 590.98 Thousand AUD | 0.0% |
| 2016 FY | 2.39 Million AUD | 410.07% |
| 2015 FY | 468.78 Thousand AUD | 51.34% |
| 2015 Q4 | 468.78 Thousand AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q4 | 309.75 Thousand AUD | 0.0% |
| 2014 FY | 309.75 Thousand AUD | -39.3% |
| 2013 Q2 | 127.57 Thousand AUD | 25.94% |
| 2013 Q1 | 101.29 Thousand AUD | 0.0% |
| 2013 FY | 510.29 Thousand AUD | 25.94% |
| 2013 Q4 | 219.56 Thousand AUD | 72.11% |
| 2013 Q3 | 127.57 Thousand AUD | 0.0% |
| 2012 Q4 | - AUD | -100.0% |
| 2012 Q2 | 101.29 Thousand AUD | 92.88% |
| 2012 Q1 | 52.51 Thousand AUD | 0.0% |
| 2012 FY | 405.17 Thousand AUD | 92.88% |
| 2012 Q3 | 101.29 Thousand AUD | 0.0% |
| 2011 Q3 | 52.51 Thousand AUD | 0.0% |
| 2011 FY | 210.06 Thousand AUD | -20.96% |
| 2011 Q2 | 52.51 Thousand AUD | -20.96% |
| 2011 Q1 | 66.43 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2010 Q2 | 66.43 Thousand AUD | 17.43% |
| 2010 Q3 | 66.43 Thousand AUD | 0.0% |
| 2010 FY | 265.75 Thousand AUD | -60.61% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | 56.57 Thousand AUD | 0.0% |
| 2009 Q2 | 56.57 Thousand AUD | 179.01% |
| 2009 Q3 | 56.57 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | -100.0% |
| 2009 Q1 | 20.27 Thousand AUD | 0.0% |
| 2009 FY | 674.61 Thousand AUD | -40.59% |
| 2008 Q3 | 20.27 Thousand AUD | 0.0% |
| 2008 Q1 | 22.78 Thousand AUD | 0.0% |
| 2008 FY | 1.13 Million AUD | -38.84% |
| 2008 Q4 | - AUD | -100.0% |
| 2008 Q2 | 20.27 Thousand AUD | -11.0% |
| 2007 FY | 1.85 Million AUD | 129.33% |
| 2007 Q4 | - AUD | -100.0% |
| 2007 Q2 | 22.78 Thousand AUD | -88.74% |
| 2007 Q1 | 202.4 Thousand AUD | 0.0% |
| 2007 Q3 | 22.78 Thousand AUD | 0.0% |
| 2006 FY | 809.6 Thousand AUD | -59.35% |
| 2006 Q2 | 202.4 Thousand AUD | -59.35% |
| 2006 Q3 | 202.4 Thousand AUD | 0.0% |
| 2006 Q1 | 497.86 Thousand AUD | 0.0% |
| 2006 Q4 | - AUD | -100.0% |
| 2005 Q3 | 497.86 Thousand AUD | 0.0% |
| 2005 Q1 | 1.07 Million AUD | 0.0% |
| 2005 Q4 | - AUD | -100.0% |
| 2005 Q2 | 497.86 Thousand AUD | -53.47% |
| 2005 FY | 1.99 Million AUD | -53.47% |
| 2004 Q3 | 1.07 Million AUD | 0.0% |
| 2004 Q4 | - AUD | -100.0% |
| 2004 FY | 4.28 Million AUD | 10.38% |
| 2004 Q1 | 997.46 Thousand AUD | 0.0% |
| 2004 Q2 | 1.07 Million AUD | 7.28% |
| 2003 Q4 | - AUD | -100.0% |
| 2003 Q1 | 322.78 Thousand AUD | 0.0% |
| 2003 Q3 | 997.46 Thousand AUD | 0.0% |
| 2003 Q2 | 997.46 Thousand AUD | 209.02% |
| 2003 FY | 3.87 Million AUD | 207.03% |
| 2002 Q1 | - AUD | 0.0% |
| 2002 Q2 | 322.78 Thousand AUD | 0.0% |
| 2002 FY | 1.26 Million AUD | 0.0% |
| 2002 Q3 | 322.78 Thousand AUD | 0.0% |
| 2002 Q4 | - AUD | -100.0% |
| 2001 Q2 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2001 Q3 | - AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | 73.507% |
| Acrux Limited | 5.09 Million AUD | 90.957% |
| Race Oncology Limited | 4 Million AUD | 88.5% |
| Biome Australia Limited | 13 Million AUD | 96.461% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | 23.499% |
| BTC Health Limited | 16.36 Thousand AUD | -2714.163% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 93.827% |
| CSL Limited | 22.41 Billion AUD | 99.998% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 95.999% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 99.478% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 99.307% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | 86.867% |
| Memphasys Limited | 60 Thousand AUD | -667.328% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 99.801% |
| Noxopharm Limited | 2.4 Million AUD | 80.819% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 87.598% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -53.862% |
| Starpharma Holdings Limited | 8.28 Million AUD | 94.446% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -202.415% |
| Biotron Limited | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 4.01 Million AUD | 88.545% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -2413.084% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -384.873% |
| Patrys Limited | 1.39 Million AUD | 66.977% |
| Orthocell Limited | 5.31 Million AUD | 91.338% |
| Imugene Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 22.05 Million AUD | 97.913% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | 48.394% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 80.118% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -2608.218% |
| Nanollose Limited | 12.5 Thousand AUD | -3582.881% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 62.021% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | 89.66% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 63.215% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.907% |
| Dimerix Limited | 583.47 Thousand AUD | 21.094% |
| PharmAust Limited | - AUD | -Infinity% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -599.691% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | 2.778% |
| Actinogen Medical Limited | 9.93 Million AUD | 95.364% |
| Immuron Limited | 4.9 Million AUD | 90.61% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 82.278% |